In the April–June 2016 edition of Corporate Disputes, Dr. Gregory K. Bell discusses disputes in the healthcare and life sciences industry. In this roundtable discussion, the panel experts describe the underlying causes of recent disputes in the sector and highlight key cases. To read the article, click the link below.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...